{"id":"medium-dosage-sars-cov-2-vaccine","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site pain or swelling"},{"rate":"10-30","effect":"Fatigue"},{"rate":"10-25","effect":"Myalgia"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4594493","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains chemically inactivated whole SARS-CoV-2 virions that cannot replicate or cause disease. When administered, these inactivated particles trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize live virus upon exposure. The medium dosage formulation is designed to balance immunogenicity with tolerability.","oneSentence":"This inactivated SARS-CoV-2 vaccine stimulates the immune system to produce antibodies and cellular immunity against the virus by presenting inactivated viral particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:14.585Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 caused by SARS-CoV-2"}]},"trialDetails":[{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT05960097","phase":"PHASE2","title":"A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-08-01","conditions":"SARS-CoV-2, COVID-19","enrollment":692},{"nctId":"NCT04798027","phase":"PHASE1, PHASE2","title":"Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-12","conditions":"COVID-19","enrollment":182},{"nctId":"NCT04839042","phase":"PHASE1","title":"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers","status":"COMPLETED","sponsor":"Moat Biotechnology Corporation","startDate":"2021-06-28","conditions":"Covid19","enrollment":196},{"nctId":"NCT05022472","phase":"PHASE4","title":"Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California","status":"COMPLETED","sponsor":"Britt Skaathun","startDate":"2021-07-16","conditions":"Vaccine Refusal, Covid19","enrollment":1051},{"nctId":"NCT05013983","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents","status":"WITHDRAWN","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2024-07","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05799651","phase":"PHASE1","title":"Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glycovax Pharma Inc.","startDate":"2023-04-28","conditions":"SARS-CoV-2","enrollment":36},{"nctId":"NCT04608305","phase":"PHASE1, PHASE2","title":"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine","status":"COMPLETED","sponsor":"Israel Institute for Biological Research (IIBR)","startDate":"2020-10-28","conditions":"Covid19","enrollment":843},{"nctId":"NCT04470609","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2020-07-10","conditions":"COVID-19","enrollment":471},{"nctId":"NCT04412538","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2020-05-15","conditions":"COVID-19","enrollment":942},{"nctId":"NCT04551547","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2020-10-31","conditions":"COVID-19","enrollment":552},{"nctId":"NCT05254236","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-02-10","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04884685","phase":"PHASE2","title":"Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-05-03","conditions":"COVID-19","enrollment":500},{"nctId":"NCT04679909","phase":"PHASE1","title":"Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2021-02-25","conditions":"Healthy Volunteers","enrollment":92},{"nctId":"NCT04824391","phase":"PHASE2","title":"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-02-10","conditions":"COVID-19","enrollment":250},{"nctId":"NCT05706324","phase":"PHASE1","title":"Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2023-06","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04691947","phase":"PHASE1","title":"Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-11-05","conditions":"COVID-19 Vaccine","enrollment":44},{"nctId":"NCT04840992","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-21","conditions":"COVID-19","enrollment":840},{"nctId":"NCT05156632","phase":"PHASE3","title":"Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2023-02-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04334980","phase":"PHASE1","title":"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","status":"COMPLETED","sponsor":"Symvivo Corporation","startDate":"2020-11-02","conditions":"COVID-19","enrollment":24},{"nctId":"NCT04545749","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","status":"COMPLETED","sponsor":"United Biomedical Inc., Asia","startDate":"2020-09-25","conditions":"COVID-19","enrollment":60},{"nctId":"NCT05165966","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-10-20","conditions":"COVID-19","enrollment":340},{"nctId":"NCT04383574","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2020-05-22","conditions":"COVID-19","enrollment":422},{"nctId":"NCT05150496","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-15","conditions":"COVID-19","enrollment":640},{"nctId":"NCT04619628","phase":"PHASE1","title":"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2020-12-11","conditions":"COVID-19","enrollment":48},{"nctId":"NCT04522089","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine","status":"COMPLETED","sponsor":"Adimmune Corporation","startDate":"2020-08-24","conditions":"COVID-19","enrollment":68},{"nctId":"NCT04671017","phase":"PHASE1, PHASE2","title":"Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2020-12-16","conditions":"SARS-CoV-2 Virus Infection","enrollment":153},{"nctId":"NCT05079217","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-12-17","conditions":"COVID-19","enrollment":1200},{"nctId":"NCT04352608","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2020-04-16","conditions":"COVID-19","enrollment":744},{"nctId":"NCT04487210","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2020-10-07","conditions":"COVID-19","enrollment":45},{"nctId":"NCT04758273","phase":"PHASE1","title":"A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)","status":"UNKNOWN","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2020-10-07","conditions":"COVID-19","enrollment":180},{"nctId":"NCT04756323","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)","status":"UNKNOWN","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2020-10-27","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04398147","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada","status":"UNKNOWN","sponsor":"CanSino Biologics Inc.","startDate":"2020-08-01","conditions":"COVID-19","enrollment":696}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CoronaVac"],"phase":"marketed","status":"active","brandName":"Medium-dosage SARS-CoV-2 vaccine","genericName":"Medium-dosage SARS-CoV-2 vaccine","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This inactivated SARS-CoV-2 vaccine stimulates the immune system to produce antibodies and cellular immunity against the virus by presenting inactivated viral particles. Used for Prevention of COVID-19 caused by SARS-CoV-2.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}